Endocrine Practice

American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings: Co-Sponsored by the American Association for the Study of Liver Diseases (AASLD).  28:528-562. 2022

Diversity, Equity and Inclusion in Endocrinology: A Survey and Vision for the Future. 2022

Attitudes, Perceptions, and Practices Among Endocrinologists Managing Obesity..  28:179-184. 2022

Is Obesity or Adiposity-Based Chronic Disease Curable: The Set Point Theory, the Environment, and Second-Generation Medications.  28:214-222. 2022

Incidental Pituitary Cysts in Children: Does Growth Hormone Treatment Affect Cyst Size?.  27:1128-1132. 2021

Pediatric Endocrinology: Perspectives of Pediatric Endocrinologists Regarding Career Choice and Recruitment of Trainees.  27:743-748. 2021

Arterial Stiffness: Comment on the Article by Pavloska et al.  27:640-641. 2021

COVID-19 & obesity: Beyond BMI.  26:923-925. 2020

The role of heteroplasmy in the diagnosis and management of maternally inherited diabetes and deafness.  26:241-246. 2020

Consensus statement by the American Association of clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm - 2020 executive summary.  26:107-139. 2020

CLINICAL PRACTICE GUIDELINES FOR THE PERIOPERATIVE NUTRITION, METABOLIC, AND NONSURGICAL SUPPORT OF PATIENTS UNDERGOING BARIATRIC PROCEDURES - 2019 UPDATE: COSPONSORED BY AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS/AMERICAN COLLEGE OF ENDOCRINOLOGY, THE OBESITY SOCIETY, AMERICAN SOCIETY FOR METABOLIC & BARIATRIC SURGERY, OBESITY MEDICINE ASSOCIATION, AND AMERICAN SOCIETY OF ANESTHESIOLOGISTS - EXECUTIVE SUMMARY.  25:1346-1359. 2019

Commentary from the American association of clinical endocrinologists on the U.S. preventive services task force recommandations regarding weight loss interventions.  25:394-395. 2019

Commentary on a direct comparison of the ATA and TI-RADS ultrasound scoring systems.  25:503-505. 2019

Consensus statement by the American association of clinical endocrinologists and American college of endocrinology on the comprehensive type 2 diabetes management algorithm – 2019 executive summary.  25:69-100. 2019

Dysglycemia-based chronic disease: An American association of clinical endocrinologists position statement.  24:995-1011. 2018

Clinical characteristics and sequelae of severe hypertriglyceridemia in pediatrics.  24:789-795. 2018

Application of the AACE/ACE advanced framework for the diagnosis of obesity and cardiometabolic disease staging in a general population from 3 regions of Venezuela: The vemsols study results.  24:6-13. 2018

Consensus statement by the American association of clinical endocrinologists and American college of endocrinology on the comprehensive type 2 diabetes management algorithm - 2018 executive summary.  24:91-120. 2018

To the editor: Author response to Dr. Zhu.  23:888. 2017

Letter to the Editor.  23:749-750. 2017

Adiposity-based chronic disease as a new diagnostic term: The American association of clinical endocrinologists and American college of endocrinology position statement.  23:372-378. 2017

CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2017 EXECUTIVE SUMMARY.  23:207-238. 2017

Patient-centered care of the patient with obesity.  22:1-21. 2016

Effects of liraglutide 3.0 mg on weight and risk factors in hispanic versus non-hipanic populations: Subgroup analysis from scale randomized trials.  22:1277-1287. 2016

American association of clinical endocrinologists and American college of endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity: Executive summary.  22:842-884. 2016

Transculturalization recommendations for developing Latin American clinical practice algorithms in endocrinology - Proceedings of the 2015 pan-American workshop by the American association of clinical endocrinologists and American college of endocrinology.  22:477-501. 2016

American association of clinical endocrinologists and American college of endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity.  22:1-203. 2016

Consensus statement by the American association of clinical endocrinologists and American college of endocrinology on the comprehensive type 2 diabetes management algorithm - 2016 executive summary.  22:84-113. 2016

Consensus statement by the American association of clinical endocrinologists and American College of endocrinology on the comprehensive type 2 diabetes management algorithm - 2015 executive summary.  21:1403-1414. 2015

Diabetes and prediabetes are significantly higher in morbidly obese children compared with obese children.  21:1046-1053. 2015

American Association of Clinical Endocrinologists and American College of Endocrinology - Clinical practice guidelines for developing a diabetes mellitus comprehensive care plan - 2015.  21:1-87. 2015

AACE/ACE comprehensive diabetes management algorithm 2015.  21:438-447. 2015

AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY--CLINICAL PRACTICE GUIDELINES FOR DEVELOPING A DIABETES MELLITUS COMPREHENSIVE CARE PLAN--2015--EXECUTIVE SUMMARY.  21:413-437. 2015

AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY - CLINICAL PRACTICE GUIDELINES FOR DEVELOPING A DIABETES MELLITUS COMPREHENSIVE CARE PLAN - 2015..  21 Suppl 1:1-87. 2015

AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY--CLINICAL PRACTICE GUIDELINES FOR DEVELOPING A DIABETES MELLITUS COMPREHENSIVE CARE PLAN--2015--EXECUTIVE SUMMARY.  21:413-437. 2015

Diabetes status and race are associated with cardiovascular risk markers in obese adolescents.  21:165-173. 2015

American association of clinical endocrinologists and american college of endocrinology consensus conference on obesity: building an evidence base for comprehensive action..  20:956-976. 2014

American association of clinical endocrinologists and american college of endocrinology position statement on the 2014 advanced framework for a new diagnosis of obesity as a chronic disease..  20:977-989. 2014

Erratum: AACE Obesity Position Statement (Endocrine Practice (2012) 18 (642-648)).  19:1072. 2013

Glycemic control and diabetic dyslipidemia in adolescents with type 2 diabetes.  19:972-979. 2013

Clinical practice guidelines for healthy eating for the prevention and treatment of metabolic and endocrine diseases in adults: Cosponsored by the American association of clinical endocrinologists/the american college of endocrinology and the obesity society: Executive summary.  19:875-887. 2013

New tools for weight-loss therapy enable a more robust medical model for obesity treatment: Rationale for a complications-centric approach.  19:864-874. 2013

American association of clinical endocrinologists' comprehensive diabetes management algorithm 2013 consensus statement.  19:1-48. 2013

Clinical practice guidelines for the perioperative nutritional, metabolic, and nonsurgical support of the bariatric surgery patient-2013 update: Cosponsored by American Association of Clinical Endocrinologists, the Obesity Society, and American Society for Metabolic & Bariatric Surgery.  19:337-372. 2013

AACE comprehensive diabetes management algorithm 2013..  19:327-336. 2013

American Association of Clinical Endocrinologists' comprehensive diabetes management algorithm 2013 consensus statement--executive summary..  19:536-557. 2013

In response.  19:170. 2013

The clinical approach to the detection of lipodystrophy - An AACE consensus statement.  19:107-116. 2013

Use of available glucose-lowering agents in patients with different levels of renal impairment.  19:14-18. 2013

American association of clinical endocrinologists' position statement on obesity and obesity medicine.  18:642-648. 2012

Safety and feasibility of laparoscopic resection for large (≥6 cm) pheochromocytomas without suspected malignancy.  18:720-726. 2012

Preoperative ultrasonography findings predict the need for repeated surgery in papillary thyroid cancer.  18:403-409. 2012

Three large, functioning cystic parathyroid adenomas.  18. 2012

Diagnosis and management of pheochromocytoma in an academic hospital 3 years after formation of a pheochromocytoma interest group.  17:356-362. 2011

Positive prolactin response to bromocriptine in 2 patients with cabergoline-resistant prolactinomas.  17. 2011

Colesevelam hydrochloride to treat hypercholesterolemia and improve glycemia in prediabetes: a randomized, prospective study..  16:617-628. 2010

Initial combination therapy with metformin and colesevelam for achievement of glycemic and lipid goals in early type 2 diabetes..  16:629-640. 2010

Evaluation of vitamin d repletion regimens to correct vitamin d status in adults.  15:95-103. 2009

Symptomatic hyperprolactinemia from an ectopic pituitary adenoma located in the clivus.  15:143-148. 2009

Visual vignette.  14:651. 2008

Diagnosis and management of prediabetes in the continuum of hyperglycemia - When do the risks of diabetes begin? A consensus statement from the American College of Endocrinology and the American Association of Clinical Endocrinologists.  14:933-946. 2008

Pheochromocytoma in patients suspected of harboring adrenal metastasis: Management and clinical predictors.  14:967-972. 2008

Visual vignette.  14:651. 2008

Vitamin D status in United States war veterans.  14:127-128. 2008

Cardiovascular disease prevention and care in latino and hispanic subjects.  13:77-85. 2007

Calciphylaxis in the absence of end-stage renal disease.  12:406-410. 2006

Reversible subclinical hypothyroidism in the presence of adrenal insufficiency.  12:572-575. 2006

Vaginal bleeding and galactorrhea in a child with ovarian steroid cell tumor.  11:346-349. 2005

Catecholamine excess in pheochromocytoma inducing insulin resistance.  10:149-152. 2004

Visual vignette.  10:384. 2004

Artifactually low hemoglobin A1c caused by use of dapsone.  8:370-372. 2002

Effect of thiazolidinediones on high-density lipoprotein subfractions.  8:102-104. 2002

Lipoprotein effects of different thiazolidinediones in clinical practice.  8:406-410. 2002

Long-term efficacy of triple oral therapy for type 2 diabetes mellitus.  8:271-275. 2002

Conversion from troglitazone to rosiglitazone.  7:326. 2001

Tissue triglyceride levels in type 2 diabetes and the role of thiazolidinediones in reversing the effects of tissue hypertriglyceridemia: Review of the evidence in animals and humans.  7:135-138. 2001

Use of soy protein supplement and resultant need for increased dose of levothyroxine.  7:193-194. 2001

How long can insulin therapy be avoided in the patient with type 2 diabetes mellitus by use of a combination of metformin and a sulfonylurea?.  6:293-295. 2000

Improved glycemic control with use of continuous subcutaneous insulin infusion compared with multiple insulin injection therapy..  6:357-360. 2000

Postprandial rather than preprandial glucose levels should be used for adjustment of rapid-acting insulins..  6:477-478. 2000

C-Peptide utilization in clinical practice: effect on treatment and outcome of diabetes in a series of cases..  5:114-118. 1999

Triple oral antidiabetic therapy in type 2 diabetes mellitus..  4:146-147. 1998